<DOC>
	<DOCNO>NCT01976208</DOCNO>
	<brief_summary>The primary purpose evaluate safety efficacy recombinant humanize anti-IgE monoclonal antibody injection patient allergic asthma .</brief_summary>
	<brief_title>Safety Efficacy Study Omalizumab Treat Allergic Asthma</brief_title>
	<detailed_description>Omalizumab give add-on treatment budesonide inhale powder patient moderate severe allergic asthma ( IgE &gt; =60IU/ml ) , demonstrate inadequate asthma symptom control . Response Omalizumab assess overall improvement control asthma . Omalizumab recombinant humanize monoclonal antibody selectively bind human immunoglobulin E ( IgE ) . The antibody molecular weight approximately 150 kilodaltons produce Chinese Hamster Ovary cell . Omalizumab inhibit bind IgE high-affinity IgE receptor surface mast cell basophil . Reduction surface-bound IgE cell limit degree release mediator allergic response .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Male female age 15~65 year Written inform consent provide Total serum IgE &gt; =60IU/ml Duration allergic asthma &gt; = 1 year accord GINA ( 2008 ) Poor response moderate high dose inhale corticosteroid ( 400ug/day~800ug/day ) &gt; = 4 week Agreed pregnant , contraception study later 6 month . Patients meet criterion exclude : Be regular smoker ( &gt; 10 cigarette per day least 2 year ) Patients currently pregnant nursing intend become pregnant course study later 6 month COPD , accord guideline Chinese society respiratory diseases An active lung disease allergic asthma Patients significant underlying medical condition Allergic immunoglobin formulation ingredient product Patients diabetes uncontrolled hypertension ( Systolic blood pressure &gt; 160mmHg Diastolic blood pressure &gt; 95mmHg ) HIV positivity cancer patient Prior exposure Xolair</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Omalizumab</keyword>
	<keyword>IgE</keyword>
	<keyword>Asthma</keyword>
</DOC>